Pancreatitis - Microbiome as Predictor of Severity II
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorUniversity Medical Center Goettingen
About this trial
The goal of this observational study is to evaluate the orointestinal microbiome and microbial derived metabolome in patients suffering from acute pancreatitis as a biomarker for severity. The main questions it aims to answer are:
* Can the orointestinal microbiome robustly predict the course of acute pancreatitis? * How does the microbiome impact the severity of an acute pancreatitis?
Buccal/ rectal swabs, plasma and stool is collected from patients with acute pancreatitis within 48h after hospital admission.
Eligibility criteria
Qualifiers
Patients with initial diagnosis (< 48h) of acute pancreatitis
Age ≥ 18 years
Patients able to understand/ give their written consent
Disqualifiers
Recurrent acute pancreatitis (>2 previous episodes)
Clinical or imaging signs of chronic pancreatitis
Referred patients with length of hospital stay > 48h
Trial design
Treatments tested in this trial
- Not listed
Trial groups
700 Participants
are grouped into 3 trial groupsSponsors and collaborators
Source ClinicalTrials.gov